Bispecific Antibodies
•38 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (38)
%
| Company | Market Cap | Price |
|---|---|---|
|
Bispecific antibodies in J&J's oncology/immunology portfolio (e.g., TECAVYLI/TALVEY) represent a distinct product category.
|
$458.89B |
$190.72
-0.67%
|
|
ABBV-383 is a bispecific antibody in AbbVie's oncology pipeline, representing a distinct bispecific antibody modality.
|
$431.71B |
$236.56
-1.80%
|
|
IO bispecifics (e.g., rilvegostomig) are highlighted as a transformative modality in AstraZeneca's pipeline.
|
$262.04B |
$84.53
-1.28%
|
|
Bispecific antibodies (T-cell engagers) are a strategic modality with assets from Harpoon/Curon acquisitions.
|
$200.78B |
$79.96
-0.16%
|
|
BLINCYTO (a bispecific T-cell engager) and the BiTE platform establish Amgen's Bispecific Antibodies capability.
|
$156.00B |
$290.13
-2.04%
|
|
The company is advancing bispecific antibodies (e.g., Lynozyfic, Odronextamab) as a key differentiated modality.
|
$60.96B |
$564.63
-0.82%
|
|
DuoBody bispecific antibody technology enables dual-target engagement, a key Genmab differentiator.
|
$21.05B |
$31.81
-0.28%
|
|
Genmab’s core Bispecific Antibodies capability (DuoBody platform) underpins assets like EPKINLY and future pipeline, a distinct investable product category.
|
$19.49B |
$315.00
|
|
Ivonescimab is a bispecific antibody (PD-1/VEGF), placing Summit in the Bispecific Antibodies investable theme.
|
$15.86B |
$21.35
-6.28%
|
|
Zanidatamab is a bispecific antibody, a key modality in Jazz's pipeline.
|
$7.99B |
$129.59
-0.16%
|
|
The pipeline includes bispecific antibodies (e.g., ZL-1503) for oncology/immunology indications.
|
$3.43B |
$31.62
+0.86%
|
|
LockBody platform suggests the potential for bispecific antibody formats that engage T cells (e.g., CD3) in cancer therapy.
|
$2.98B |
$22.31
-2.75%
|
|
CDX-622 is described as a bispecific antibody, placing Celldex in the Bispecific Antibodies category.
|
$1.74B |
$26.14
+1.79%
|
|
NKTR-0166 bispecific antibody program representing a bispecific antibody therapeutic modality.
|
$1.08B |
$58.85
+2.65%
|
|
Obexelimab is a bispecific antibody, a dual-target therapeutic modality
|
$963.44M |
$23.03
+5.84%
|
|
Dual-masked T-cell engagers constitute bispecific antibody therapeutics with engineered safety profiles.
|
$758.93M |
$5.49
+5.98%
|
|
Xencor's XmAb platform centers on engineered bispecific antibodies (e.g., XmAb2+1 formats) and a pipeline of T-cell engager therapies.
|
$735.19M |
$10.33
-0.29%
|
|
ERAS-12 is an EGFR D2D3 biparatopic antibody, i.e., a bispecific antibody modality.
|
$685.56M |
$2.42
+13.08%
|
|
KSI-501 and KSI-101 are bispecific antibodies, a core modality in Kodiak's pipeline.
|
$626.30M |
$11.87
-11.42%
|
|
CMPX develops proprietary bispecific antibodies (e.g., tovecimig, CTX-8371, CTX-10726), the core product category they directly design and advance.
|
$586.32M |
$4.24
+4.18%
|
|
Sonelokimab is a tri-specific nanobody engaging multiple targets, aligning with Bispecific Antibodies.
|
$541.24M |
$8.43
+11.95%
|
|
Direct product category: bispecific antibody therapeutics developed for immuno-oncology.
|
$388.95M |
$4.77
-1.65%
|
|
Platform includes masked T-cell engagers, i.e., bispecific antibody formats targeting tumors.
|
$266.05M |
$3.30
+1.23%
|
|
Bispecific Antibodies reflects CGEN's involvement in bispecific modalities like rilvegostomig (PD-1/TIGIT) and related components.
|
$165.64M |
$1.85
-5.13%
|
|
Direct product category: bispecific antibodies (PD-L1xVEGF) developed/distributed by the company.
|
$126.15M |
$19.23
-8.43%
|
|
Shattuck is developing DR3 bispecific antibodies in its preclinical pipeline, a distinct antibody modality.
|
$109.21M |
$2.28
+1.33%
|
|
LORIGELimab is a PD-1 x CTLA-4 bispecific antibody; MacroGenics has multiple bispecific antibody programs.
|
$106.62M |
$1.69
-4.52%
|
|
Develops bispecific antibodies (e.g., CD3-engagers) using its POWERbody platform.
|
$86.33M |
$1.95
-1.52%
|
|
CNTX's core product category is T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$81.01M |
$0.89
-1.06%
|
|
WTX-1011 is a T-cell engager, aligning with the Bispecific Antibodies category.
|
$73.14M |
$1.63
-9.94%
|
|
AN8025 is a tri-specific antibody fusion protein, fitting the bispecific/multi-specific antibody therapeutics category.
|
$57.88M |
$1.57
-7.10%
|
|
BA3182 is a bispecific antibody (EpCAM x CD3) T-cell engager, a distinct CAB modality.
|
$50.68M |
$0.87
-17.38%
|
|
Xilio's masked T cell engager programs are bispecific antibodies, a direct therapy modality.
|
$43.64M |
$0.84
-5.31%
|
|
Bolt's collaboration with Genmab on next-generation bispecific ISACs positions the company in the bispecific antibody space.
|
$11.12M |
$5.80
-1.60%
|
|
Bispecific antibodies (HS1940, HS3215) leveraging dual-target engagement.
|
$7.93M |
$2.98
-7.45%
|
|
CBIO is pursuing bispecific antibody therapy (PD-1 x VEGF), representing a prominent investable category.
|
$7.32M |
$11.35
-6.81%
|
|
INB-600 is a T cell engager platform, i.e., a bispecific antibody engager design targeting gamma-delta T cells.
|
$6.35M |
$2.10
-7.08%
|
|
HCWB's TRBC-derived constructs include multi-specific targeting fusions and immune cell engagers, aligning with Bispecific Antibodies.
|
$5.84M |
$4.06
-10.77%
|
Loading industry metrics...
Loading comparison data...
